Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Omega Therapeutics, Inc. OMGA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
45/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.00
+6211.4%

Omega Therapeutics, Inc. (OMGA) is a Biotechnology company in the Healthcare sector, currently trading at $0.14. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is OMGA = $9 (+6211.4% upside).

Financials: revenue is $3M, +694.4%/yr average growth. Net income is $97M (loss), growing at -57.4%/yr. Net profit margin is -3148.9% (negative). Gross margin is -2028.9% (-1165.7 pp trend).

Balance sheet: total debt is $128M against $58M equity (Debt-to-Equity (D/E) ratio 2.21, leveraged). Current ratio is 3.35 (strong liquidity). Debt-to-assets is 62.8%. Total assets: $204M.

Analyst outlook: 6 / 7 analysts rate OMGA as buy (86%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 0/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).

$9.00
▲ 6211.36% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Omega Therapeutics, Inc., the average price target is $9.00, with a high forecast of $11.00, and a low forecast of $7.00.
Highest Price Target
$11.00
Average Price Target
$9.00
Lowest Price Target
$7.00

OMGA SharesGrow Score Overview

62/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OMGA

✓
VALUE Pass
100/100
OMGA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $9, implying +6211.4% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
OMGA: +694.4%/yr revenue is, -57.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet OMGA: Debt-to-Equity (D/E) ratio 2.21 (leveraged), Current ratio is 3.35 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✓
FUTURE Pass
94/100
Analyst outlook: 6 / 7 analysts rate OMGA as buy (86%). Analyst consensus target is $9 (+6211.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
OMGA: Net profit margin is -3148.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.0251-4.4396
Volume4.28M
Avg Volume (30D)9.59M
Market Cap$7.9M
Beta (1Y)1.64
Share Statistics
EPS (TTM)-1.80
Shares Outstanding$54.01M
IPO Date2021-07-30
Employees93
CEOKaan Certel
Financial Highlights & Ratios
Revenue (TTM)$3.09M
Gross Profit$-62.78M
EBITDA$-93.49M
Net Income$-97.43M
Operating Income$-100.26M
Total Cash$73.43M
Total Debt$128.43M
Net Debt$59.99M
Total Assets$204.37M
Price / Earnings (P/E)-0.1
Price / Sales (P/S)2.55
Analyst Forecast
1Y Price Target$9.00
Target High$11.00
Target Low$7.00
Upside+6,211.4%
Rating ConsensusBuy
Analysts Covering7
Buy 86% Hold 14% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS68217N1054

Price Chart

Track all markets on TradingView
OMGA
Omega Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.03 52WK RANGE 4.44

People Also View

CNTA
CNTA
Centessa Pharmaceuticals plc
$39.59
+0.05%
 GPCR
GPCR
Structure Therapeutics Inc.
$53.19
-1.95%
 ELVN
ELVN
Enliven Therapeutics, Inc.
$44.85
+2.33%
 PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 OLMA
OLMA
Olema Pharmaceuticals, Inc.
$16.30
+2.32%
 MLTX
MLTX
MoonLake Immunotherapeutics
$18.78
+1.90%
 CMPX
CMPX
Compass Therapeutics, Inc.
$5.44
+4.62%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message